CN118019727A - 用于制备nlrp3抑制剂的方法 - Google Patents

用于制备nlrp3抑制剂的方法 Download PDF

Info

Publication number
CN118019727A
CN118019727A CN202280045202.0A CN202280045202A CN118019727A CN 118019727 A CN118019727 A CN 118019727A CN 202280045202 A CN202280045202 A CN 202280045202A CN 118019727 A CN118019727 A CN 118019727A
Authority
CN
China
Prior art keywords
group
typically
piperidine
solvent
protected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045202.0A
Other languages
English (en)
Chinese (zh)
Inventor
P·弗雷泽
J·帕尔古纳
M·巴拉塔
J·E·F·辛奎布雷
R·J·G·蒙迪雷
P·托萨蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN118019727A publication Critical patent/CN118019727A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98Nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280045202.0A 2021-06-23 2022-06-23 用于制备nlrp3抑制剂的方法 Pending CN118019727A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202141028180 2021-06-23
IN202141028180 2021-06-23
PCT/EP2022/067126 WO2022268935A2 (en) 2021-06-23 2022-06-23 Novel process

Publications (1)

Publication Number Publication Date
CN118019727A true CN118019727A (zh) 2024-05-10

Family

ID=82458485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045202.0A Pending CN118019727A (zh) 2021-06-23 2022-06-23 用于制备nlrp3抑制剂的方法

Country Status (12)

Country Link
US (1) US20240150291A1 (enExample)
EP (1) EP4359385A2 (enExample)
JP (1) JP2024524215A (enExample)
KR (1) KR20240024842A (enExample)
CN (1) CN118019727A (enExample)
AR (1) AR126215A1 (enExample)
AU (1) AU2022300325A1 (enExample)
CA (1) CA3219597A1 (enExample)
IL (1) IL308071A (enExample)
MX (1) MX2023014547A (enExample)
TW (1) TW202317514A (enExample)
WO (1) WO2022268935A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023220628A1 (en) * 2022-02-15 2024-05-23 F. Hoffmann-La Roche Ag Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
WO2024133610A1 (en) * 2022-12-23 2024-06-27 F. Hoffmann-La Roche Ag Proccesses for the preparation of an nlrp3 inhibitor
WO2025036914A1 (en) 2023-08-16 2025-02-20 F. Hoffmann-La Roche Ag Process for the preparation of preparing 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)piperidine-4-sulfonamide
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA917435B (en) * 1990-09-26 1992-05-27 Takeda Chemical Industries Ltd Herbicides
CA2059450A1 (en) * 1991-01-24 1992-07-25 Nobuyuki Sakashita Subsituted pyridinesulfonamide compound or its salt, process for preparing the same, and herbicide containing the same
JP2001518069A (ja) * 1997-05-02 2001-10-09 ドクター・レディーズ・リサーチ・ファウンデーション 低脂質性、抗高血圧性特性を有する新規な抗糖尿病化合物、それらの製造方法及びそれらを含有する薬学的組成物
ATE342266T1 (de) * 2000-11-16 2006-11-15 Sankyo Co 1-methylcarbapenemderivate
US7199147B2 (en) * 2001-06-12 2007-04-03 Dainippon Sumitomo Pharma Co., Ltd. Rho kinase inhibitors
MXPA04010172A (es) * 2002-04-18 2005-02-03 Schering Corp 1-(4-piperidinil)benzimidazolonas como antagonistas de histamina h3).
US7759387B2 (en) * 2003-10-08 2010-07-20 Piramal Life Sciences Limited Fibrinogen receptor antagonists and their use
DOP2006000009A (es) * 2005-01-13 2006-08-15 Arena Pharm Inc Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina
US8614215B2 (en) * 2007-02-22 2013-12-24 Merck Serono Sa Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks)
US20120196889A1 (en) * 2009-02-25 2012-08-02 H. Lundbeck A/S Catecholamine derivatives and prodrugs thereof
JP5898962B2 (ja) * 2012-01-11 2016-04-06 東京応化工業株式会社 レジスト組成物及びレジストパターン形成方法
EP3383853B1 (en) * 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
KR102669722B1 (ko) * 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
GB201712282D0 (en) * 2017-07-31 2017-09-13 Nodthera Ltd Selective inhibitors of NLRP3 inflammasome
SG11202001164SA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
KR20210018199A (ko) * 2018-03-26 2021-02-17 씨4 테라퓨틱스, 인코포레이티드 이카로스의 분해를 위한 세레블론 결합제
MA52489A (fr) * 2018-05-04 2021-03-10 Inflazome Ltd Nouveaux composés
CA3113573A1 (en) * 2018-09-21 2020-03-26 Novartis Ag Isoxazole carboxamide compounds and uses thereof
GB201817038D0 (en) 2018-10-19 2018-12-05 Inflazome Ltd Novel processes
GB201819083D0 (en) * 2018-11-23 2019-01-09 Inflazome Ltd Novel compounds
WO2020157069A1 (en) * 2019-01-28 2020-08-06 NodThera Limited Amino heterocyclic compounds and uses thereof
CN111393415B (zh) * 2020-04-30 2020-11-20 苏州信诺维医药科技有限公司 一种杂芳腈类化合物及其应用

Also Published As

Publication number Publication date
AR126215A1 (es) 2023-09-27
US20240150291A1 (en) 2024-05-09
TW202317514A (zh) 2023-05-01
AU2022300325A8 (en) 2023-11-16
MX2023014547A (es) 2024-04-29
AU2022300325A1 (en) 2023-11-02
JP2024524215A (ja) 2024-07-05
WO2022268935A3 (en) 2023-02-02
KR20240024842A (ko) 2024-02-26
IL308071A (en) 2023-12-01
EP4359385A2 (en) 2024-05-01
CA3219597A1 (en) 2022-12-29
WO2022268935A2 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
EP4359385A2 (en) Process for the preparation of nlrp3 inhibitors
TWI915407B (zh) Apol1抑制劑及其使用方法
JP2025527298A (ja) 三環式化合物及びその医薬用途
WO2014059938A1 (zh) 一种利拉列汀重要中间体的制备方法
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
AU2017304952A1 (en) Isoquinolinone compound and use thereof in preparation of antiviral drugs
CN110139868B (zh) 制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法
KR20190084299A (ko) 피롤로 6-원 헤테로방향족 고리 유도체의 제조 방법 및 그의 중간체
EP3280417A1 (en) Xanthine-substituted alkynyl carbamates/reverse carbamates as a2b antagonists
TW202543613A (zh) 作為glp-1r激動劑的新型化合物及其用途
KR102477924B1 (ko) 인돌 카르복스아미드 화합물을 제조하는 방법
AU2023220628A1 (en) Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives
CN120584100A (zh) 用于制备nlrp3抑制剂的方法
HK40105889A (zh) 用於制备nlrp3抑制剂的方法
JP2024532558A (ja) チエノ縮合環化合物及びその調製方法と使用
WO2017021904A1 (en) Daclatasvir free base and process for the preparation thereof
EP1720867B1 (en) Process for the preparation of ziprasidone
HK40112968A (zh) 用於制备1,2,3,5,6,7-六氢-s-二环戊二烯并苯衍生物的方法
WO2007062335A2 (en) New pleuromutilin derivative and its use
CN118234729A (zh) 用于制备双环甘氨酸-脯氨酸化合物和其单环甘氨酸-脯氨酸中间体的方法
CN117263850A (zh) 一种雷芬那辛的合成方法
CN118239883A (zh) 一类赖氨酸特异性脱甲基酶1(lsd1)抑制剂的制备方法
EA048927B1 (ru) Гидроксигетероциклоалканкарбамоильные производные
IL325043A (en) Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide
HK40012866A (en) Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40105889

Country of ref document: HK